СПИСОК ЛИТЕРАТУРЫ
1. Draper К., Ley С., Parsonnet J. A survey of probiotic use practices among patients at a tertiary medical centre. Benef Microbes (2017) 8 (3): 345-51. doi:10.3920/BM2016.0148. 2. Hill C., Guarner F., Reid G., Gibson G. R., Merenstein D. J., Pot B., et al. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol Hepat (2014) 11 (8): 506-14. doi: 10.1038/nrgastro.2014.66.
3. McFarland L. V. From yaks to yogurt: the history, development and current use ofprobiotics. Clin. Infect. Dis. (2015) 60 (S2): S85-90. doi:10.1093/cid/civ054.
4. Cruchet S., Fumes R., Maruy A., Hebei E., Palacios J., Medina F., et al. The Use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr. Drugs (2015) 17 (3): 199— 216. doi:10.1007/s40272-015-0124-6.
5. Szajewska H., Canani R. B., Guarino A., Hojsak L, Indrio F., Kolacek S., et al. Probiotics for the prevention of antibiotic-associated diarrhea in children. /. Pediatr. Gastroenterol. Nutr. (2016) 62 (3): 495-506. doi: 10.1097/MPG.0000000000001081.
6. Khatri L, Tomar R., Ganesan K., Prasad G. S., Subramanian S. Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii. Sci. Rep. (2017) 7 (1): 371-82. doi:10.1038/s41598-017-00414-2.
7. Azai's-Braesco V., Bresson J. L., Guarner F., Corthier G. Not all lactic acid bacteria are probiotics... but some are. Br. /. Nutr. (2010) 103 (7): 1079-81. doi: 10.1017/S0007114510000723. 8. McFarland L. V. Application of meta-analysis to specific research fields: lessons learned. World J. of Meta-Anal. (2015) 3 (4): 188-92. doi:10.13105/wjma.v3.i4.188. 9. Szajewska H. Pooling data on different probiotics is not appropriate to assess the efficacy of probiotics. Ear. /. Pediatr. (2014) 173 (7): 975. doi:10.1007/S00431-014- 2340-4.
10. Goldstein E. J., Tyrrell K. L., Citron D. M. Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin. Infect. Dis. (2015) 60 (Suppl. 2): S98-107. doi:10.1093/cid/civ072.
11. Millette M., Nguyen A., Amine К. M., Lacroix M. Gastrointestinal survival of bacteria in commercial probiotic products. Intern. J. Probiotics Prebiotics (2013) 8 (4): 149-56.
12. Domig K. J., Kiss H., Petricevic L., Viernstein H., Unger F., Kneifel W. Strategies for the evaluation and selection of potential vaginal probiotics from human sources: an exemplary study. Benef. Microbes (2014) 5 (3): 263-72. doi:10.3920/BM2013.0069.
13. McFarland L. V. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open (2014) 4 (8): e005047. doi:10.1136/bmjopen-2014-005047.
14. McFarland L. V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. (2010) 16(18): 2202-22. doi: 10.3748/wjg.vl6.il8.2202.
15. McFarland L. V., Malfertheiner P., Huang Y., Wang L. Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events. World ]. Meta-Anal. (2015) 3 (2): 97-117. doi: 10.13105/wjma.v3.i2.97.
16. McFarland L. V., Huang Y., Wang L., Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European J. Gastroenterol. (2016) 4 (4): 546-61. doi:10.1177/2050640615617358.
17. Guyatt G. H., Oxman A. D., Schiinemann H. J., Tugwell P., Knottnerus A.
GRADE guidelines: a new series of articles in the journal of clinical epidemiology. /. Clin. Epidemiol. (2011) 64 (4): 380-2. doi:10.1016/j.jclinepi.2010.09.011.
18. Donelli G., Vuotto C., Mastromarino P. Phyenotyping and genotyping are both essential to identify and classify a probiotic microorganism. Micro Ecol. Health- Dis. (2013) 3:24. doi:10.3402/mehd.v24i0.20105.
19. Dietrich C. G., Kottmann T., Alavi M. Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea.
World J. Gastroenterol. (2014) 20 (42): 15837-44. doi: 10.3748/wjg.v20.i42.15837.
20. Hickson M., D'Souza A. L., Muthu N., Rogers T. R., Want S., Rajkumar C., et al.
Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo-controlled trial. BMJ (2007) 335 (7610): 80-3.doi:10.1136/bmj.39231.599815.55.
21. Cimperman L., Bayless G., Best K., Diligente A., Mordarski B., Oster M., et al.
A randomized double blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized
adults. J. Clin. Gastroenterol. (2011) 45 (9): 785-9.
doi: 10.1097/MCG.0b013e3182166a42.
22. Ojetti V., Bruno G., Ainora M. E., Gigante G., Rizzo G., Roccarina D., et al.
Impact of Lactobacillus reuteri supplementation on anti-Helicobacter pylori levo flox-acin-based second-line therapy. Gastroenterol. Res. Pract. (2012) 2012: 740381. doi:10.1155/2012/740381.
23. Scaccianoce G., Zullo A., Hassan C., Gentili F., Cristofari F., Cardinale V., et al.
Triple therapies plus different probiotics for Helicobacter pylori eradication.
Eur. Rev. Med. Pharmacol. Sci. (2008) 12:251-6.
24. Armuzzi A., Cremonini F., Ojetti V., Bartolozzi F., Canducci F., Candelli M., et al.
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion (2001) 63 (1): 1-7. doi: 10.1159/000051865.
25. Armuzzi A., Cremonini F., Bartolozzi F., Canducci F., Candelli M., Ojetti V., et al.
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.
Aliment. Pharmacol. Ther. (2001) 15 (2): 163-9. doi:10.1046/j.l365-
2036.2001.00923.x.
26. Cremonini F., Di Caro S., Covino M., Armuzzi A., Gabrielli M., Santarelli L, et al.
Effect of different probiotic preparations on anti-Helicobacter pylori therapy- related side effects: a parallel group, triple blind, placebo-controlled study. Am J.
Gastroenterol (2002) 97 (11): 2744-9. doi: 10.1111/j. 1572-0241.2002. 07063.x.
27'. Miller M., Florencio S., Eastmond J., Reynolds S. Results of 2 prospective randomized studies of Lactobacillus GG to prevent C. difficile infection in hospitalized adults receiving antibiotics. Abstr. Intersci. Conf. Antimicrob. Agents (2008): 578-9.
28. Padilla-Ruiz M., Fernandez Aguiar M. E., Arce Nunez M., Polo Amorin R. [Lactobacillus rhamnosus GG supplementation to reduce side-effects of anti- Helicobacter pylori treatment]. Rev. Gastroenterol. Peru (2013) 33 (2): 121-30.
29. Thomas M. R., Litin S. C., Osmon D. R., Corr A. P., Weaver A. L., Lohse С. M.
Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin. Proc. (2001) 76 (9): 883-9. doi:10.4065/76.9.883.
30. Beausoleil M., Fortier N., Guenette S., Lecuyer A., Savoie M., Franco M., et al.
Effect of a fermented milk combining Lactobacillus acidophilus CU285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can. /. Gastroenterol. (2007) 21 (11): 7326. doi: 10.1155/2007/720205.
31. Gao X. W., Mubasher M., Fang C. Y„ Reifer C., Miller L. E. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J. Gastroenterol. (2010) 105 (7): 1636-41. doi:10.1038/ajg.2010.11.
32. Sampalis J., Psaradellis E., Rampakakis E. Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea - a placebo-controlled double-blind randomized, multi-center study. Arch. Med. Sci. (2010) 6 (1): 56-64. doi: 10.5114/aoms.2010.13508.
33. Bhalla A. Randomized placebo-controlled, double blind, multicentric trial on efficacy and safety of probiotic capsules (Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12) for prevention of antibiotic-associated diarrhea in Indian patients [in: abstracts: 40th annual meeting of the American college of clinical pharmacology; September 11-13, 2011; Chicago, IL]. ]. Clin. Pharmacol. (2011) 51 (9): 1327. doi:10.1177/0091270010418046.
34. Sheu B. S., Wu J. J., Lo C. Y., Wu H. W., Chen J. H., Lin Y. S., et al. Impact of supplement with Lactobacillus- and Bifidobacterium containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. (2002) 16: 1669-75. doi:10.1046/j.l365-2036.2002.01335.x.
35. Sheu B. S., Cheng H. C., Kao A. W., Wang S. T„ Yang Y. J., Yang H. B., et al.
Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J. Clin. Nutr. (2006) 83: 864-9. doi:10.1093/ajcn/83.4.864.
36. De Vrese M., Kristen H., Rautenberg P., Laue C., Schrezenmei J. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity.
J. Dairy Res. (2011) 78 (4): 396-403. doi:10.1017/S002202991100063X.
37. Mirzaee V., Rezahosseini O. Randomized control trial: comparison of triple therapy plus probiotic yogurt vs. standard triple therapy on Helicobacter pylori eradication. Iran Red. Crescent Med. /. (2012) 14 (10): 657-66.
38. Chatterjee S., Kar P., Das T., Ray S., Gangulyt S., Rajendiran C., et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J. Assoc. Physicians. India (2013) 61 (10): 708-12.
39. Evans M., Salewski R. P., Christman M. C., Girard S. A., Tompkins T. A.
Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial. Br. /. Nutr. (2016) 116 (1): 94-103. doi:10.1017/S0007114516001665.
40. Song H. J., Kim J. Y., Jung S. A., Kim S., Park H., Jeong Y., et al. Effect of probiotic Lactobacillus (Lacidofil* cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study. J. Korean Med. Sci. (2010) 25: 1784-91. doi:10.3346/jkms.2010.25.12.1784.
41. Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M. W., et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur. J. Gastroenterol. Hepatol. (2014) 26 (6): 630-9. doi:10.1097/MEG.0000000000000094.
42. Choi С. H., Jo S. Y., Park H. J., Chang S. K., Byeon J. S., Myung S. J. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J. Clin. Gastroenterol. (2011) 45 (8): 679-83. doi: 10.1097/MCG.0b013e318204593e.
43. Maupas J. L., Champemont P., Delforge M. Treatment of irritable bowel syndrome. Double blind trial of Saccharomyces boulardu. Med. Chirurgie Dig. (1983) 12 (1): 77-9.
44. Kabir M. A., Ishaque S. M., Ah M. S., Mahmuduzzaman M., Hasan M. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome.
Mymensingh Med. J. (2011) 20 (3): 397-401.
45. Pineton de Chambrun P., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., et al. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig. Liv. Dis. (2015) 47 (2): 119-24. doi:10.1016/j.dld.2014.11.007.
46. Spiller R., Pelerin F., Cayzeele Decherf A., Maudet C., Housez B., Cazaubiel M., et al. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM 1-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterol.
J. (2016) 4 (3): 353-62. doi:10.1177/2050640615602571.
47. McFarland L. V., Ozen M., Dinleyici E. C., Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J.
Gastroenterol. (2016)22 (11): 3078-104. doi: 10.3748/wjg.v22.il 1.3078.
48. Vaisanen M. L., Leskinen M., Siitonen A., Kanervo A., Harila-Saari A., Mottonen M., et al. Occurrence of diarrhea in children receiving oral antibiotics with or without probiotic supplementation with Lactobacillus GG. Micro Ecol. Health Dis. (1998) 10: 199-200.
49. Arvola T., Laiho K., Torkkeli S., Mykkanen H., Salminen S., Maunula L., et al.
Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics (1999) 104 (5): e64. doi:10.1542/peds.l04.5.e64.
50. Vanderhoof J. A., Whitney D. B., Antonson D. L., Hanner T. L., Lupo J. V., Young R. J.. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children./. Pediatr. (1999) 135 (5): 564-8. doi:10.1016/S0022-3476(99)70053-3.
51. Szajewska H., Albrecht P., Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of Lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J. Pediatr. Gastroenterol. Nutr. (2009) 48 (4): 431-6. doi:10.1097/MPG.0b013e318182e716.
52. Bousvaros A., Guandalini S., Baldassano R. N., Botelho C., Evans J., Ferry G. D., et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel. Dis. (2005) 11 (9): 833-9. doi:10.1097/01.MIB.0000175905.00212.2c.
53. Prantera C., Scribano M. L. Probiotics and Crohn's disease. Dig. Liver Dis. (2002) 34 (Suppl. 2): S66-7. doi:10.1016/S1590-8658(02)80168-2.
54. Schultz M., Timmer A., Herfarth H. H., Sartor R. B., Vanderhoof J. A., Rath H. C.. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. (2004) 4: 5. doi:10.1186/1471-230X-4-5.
55. Zocco M. A., Zileri Dal Verme L., Armuzzi A., Nista E. C., Papa A., Candelli M. Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Abstract #S1352. Digestive disease week meeting, May 17-27, 2003. Gastroenterology (2003) 124 (4): A201. doi:10.1016/S0016-5085(03)81006-5.
56. Morrow L. E., Kollef M. H., Casale T. B. Probiotic prophylaxis of ventilator- associated pneumonia: a blinded, randomized, controlled trial. Am J. Respir. Crit. Care Med. (2010) 182 (8): 1058-64. doi:10.1164/rccm.200912-18530C.
57. Hojsak I., Abdovic S., Szajewska H., Milosevic M., Krznaric Z., Kolacek S. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections: a randomized, placebo-controlled, double-blind study. Pediatrics (2010) 125 (5): ell71-6. doi:10.1542/peds.2009-2568.
58. Honeycutt T. C., El Khashab M., Wardrop R. M. Ill, McNeal-Trice K., Honeycutt A. L., Christy C. G., et al. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr. Crit. Care Med. (2007) 8 (5): 452-8.
doi: 10.1097/01 .PCC.0000282176.41134.E6.
59. Mastretta E., Longo P., Laccisaglia A., Balbo L., Russo R., Mazzaccara A., et al.
Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J. Pediatr. Gastroenterol. Nutr. (2002) 35 (4): 527-31. doi: 10.1097/00005176-200210000-00013.
60. Szajewska H., Kotowska M., Mrukowicz J. Z., Armanska M., Mikolajczyk W.
Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. /. Pediatr. (2001) 138 (3): 361-5. doi:10.1067/mpd.2001.111321.
61. Hilton E., Kolakowski P., Singer C., Smith M. Efficacy of Lactobacillus GG asaiarrheal preventive in travelers. J. Travel. Med. (1997) 4 (1): 41-3. doi: 10. I l l 1/j. 1708-8305.1997.tb00772.x.
62. Oksanen P. J., Salminen S., Saxelin M., Hamalainen P., Ihantola-Vormisto A., Muurasniemi-Isoviita L., et al. Prevention of travellers' diarrhoea by Lactobacillus GG. Ann. Med. (1990) 22 (1): 53-6. doi: 103109107853899009147242.
63. Goldenberg J. Z., Lytvyn L., Steurich J., Parkin P., Mahant S., Johnston В. C.
Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst. Rev. (2015) (12): CD004827. doi:10.1002/14651858.
64. Hempel S., Newberry S. J., Maher A. R., Wang Z., Miles J. N., Shanman R., et al.
Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA (2012) 307 (18): 195969.doi:10.1001/jama.2012.3507.
65. Sun J., Buys N. J.. Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials. Br. J. Nutr. (2016) 115 (7): 1167-77. doi:10.1017/S0007114516000076.
66. Lau C. S., Chamberlain R. S. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int. J. Gen.
Med. (2016) 9: 27-37. doi: 10.2147/IJGM.S98280.
67. Lu M., Yu S., Deng J., Yan Q., Yang C., Xia G., et al. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One (2016) 11 (10): eO 163743. doi:10.1371/journal.pone.0163743.
68. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis.
Exp. Ther. Med. (2015) 9 (3): 707-16. doi:10.3892/etm.2015.2174.
69. Zhang Y., Lixiang L., Guo C., Mu D., Feng B., Zuo X., et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. (2016) 16: 62. doi:10.1186/sl2876-016-0470-z.
70. McFarland L. V., Goh S. Preventing pediatric antibiotic-associated diarrhea and Clostridium difficile infections with probiotics: a meta-analysis. World J. Meta Anal. (2013) 1 (3): 102-20. doi:10.13105/wjma.vl.i3.102.
71. McFarland L. V.. An observation on inappropriate probiotic sub-group classifications in the meta-analysis by Lau and Chamberlain. Int. J. Gen. Med. (2016) 9: 333-6. doi:10.2147/IJGM.Sl 19970.
72. McFarland L. V.. Importance of subgroup analysis in probiotic meta-analyses. Letter to the editor. Br. J. Nutr. (2016) 116: 375-6. doi: 10.1017/S0007114516002026.
73. Glanville J., King S., Guarner F., Hill C., Sanders M. E. A review of the systematic review process and its applicability for use in evaluating evidence for health claims on probiotic foods in the European Union. Nutr. J. (2015) 14: 16-24. doi:10.1186/sl2937-015-0004-5.
74. Hill C., Scott K., Klaenhammer T. R., Quigley E., Sanders M. E. Probiotic nomenclature matters. Gut Microbes (2016) 7 (1): 1-2. doi:10.1080/19490976.2015.1127484.
75. Szajewska H., Horvath A., Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol. Ther. (2015) 41 (12): 1237-45. doi:10.1111/apt.l3214.
76. Szajewska H., Ruszczynski M., Kolacek S. Meta-analysis shows limited evidence for using Lactobacillus acidophilus LB to treat acute gastroenteritis in children.
Acta Paediatr. (2014) 103 (8): 249-55. doi:10.1111/apa.l2487.
77. Urbancsek H., Kazar T., Mezes L, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of antibiophilus in patients with radiation-induced diarrhoea. Eur. ]. Gastroenterol. Hepatol. (2001) 13: 391-6. doi:10.1097/00042737-200104000-00015.
78. Yuan F„ Ni H„ Asche С. V., Kim M„ Walayat S., Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta analysis. Curr. Med. Res. Opin. (2017) 33 (7): 1191-7. doi: 10.1080/03007995.2017.1292230.
79. Allen A. P., Clarke G., Cryan J. F., Quigley E. M. M., Dinan T. G.. Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms and mechanisms. Curr. Med. Res. Opin. (2017) 33 (7): 1349-51. doi:10.1080/03007995.2017.1322571.